Belpointe Asset Management LLC Galectin Therapeutics Inc Transaction History

Belpointe Asset Management LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 08, 2023	BUY	$1.03 - $1.66 $1,097 - $1,769	1,066 New	1,066 $1,000
Q3 2019 Jan 16, 2020	SELL	$3.0 - $4.05 $87,684 - $118,373	-29,228 Closed	0 $0
Q2 2019 Nov 22, 2019	BUY	$3.61 - $5.0 $8,050 - $11,150	2,230 Added 8.26%	29,228 $0
Q1 2019 Jun 11, 2019	BUY	$3.86 - $6.02 $104,212 - $162,527	26,998 New	26,998 $138,000
Q4 2018 Mar 06, 2019	SELL	$3.43 - $5.74 $106,772 - $178,680	-31,129 Closed	0 $0
Q3 2018 Nov 23, 2018	SELL	$3.68 - $6.93 $45,731 - $86,119	-12,427 Reduced 28.53%	31,129 $187,000
Q2 2018 Aug 06, 2018	BUY	$3.16 - $9.16 $137,636 - $398,972	43,556 New	43,556 $277,000

9.65M

1.16M

1.98M

Ticker GALT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,426,000
Market Cap $123M
Description
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial f...

Get notified when there are updates to the investment portfolio of Belpointe Asset Management LLC, based on Form 13F filings with the SEC.

Stay updated on Belpointe Asset Management LLC with notifications on news.